ANVS News and Press, Annovis Bio Inc. From 11/24/25

MALVERN, Pa., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's ...

2025-11-18 10:50:00 ET Annovis Bio (NYSE: ANVS) a late-stage clinical drug platform company developing therapies for neurodegenerative diseases including Alzheimer’s and Parkinson’s, announced that the FDA has scheduled a Type C meeting in January 2026 to discuss the clini...

2025-11-18 08:45:11 ET New York, NY – October 18, 2025 – The advance anti-aging therapies market is expanding quickly fueled by a larger senior population and increased consumer focus on preventive and longevity-focused health. A report from Grand View Research said that t...

MALVERN, Pa., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's ...

A look at the top 10 most actives in the United States UTime Limited (WTO) rose 24.3% to $0.0297 on volume of 848,521,937 shares Direxion Daily Semiconductor Bear 3X Shares (SOXS) rose 8.1% to $4.172 on volume of 288,064,226 shares Applied Therapeutics Inc. (APLT) rose 26.6% to $0.27635 on ...

2025-11-17 15:21:56 ET DENVER, Colo., Nov 17, 2025 ( 247marketnews.com )- Monday’s Power Hour is shaping up to be one of the most catalyst-heavy sessions in weeks, with traders zeroing in on a handful of names delivering blockbuster data, strategic developments, and rare commerci...

2025-11-17 09:45:00 ET Annovis Bio (NYSE: ANVS) released new findings from its Phase 3 early Parkinson’s disease study showing that buntanetap halted cognitive decline across all patients and delivered the strongest benefit in those with mild dementia and amyloid co-pathology, a ...

Buntanetap significantly improves cognition in all Parkinson’s patients, with those exhibiting Alzheimer’s co-pathology showing a three-times greater response New data demonstrate reductions in plasma biomarkers pTau217, total tau, and brain-derived tau following buntanetap ...

2025-11-12 12:00:00 ET NRx Pharmaceuticals (NASDAQ: NRXP) , a clinical-stage biopharmaceutical company, announced it will release its third quarter 2025 financial results before market open on Monday, Nov. 17, 2025, followed by a conference call at 8:30 a.m. ET to discuss corporate, fin...

2025-11-12 10:45:00 ET Annovis Bio (NYSE: ANVS) , a late-stage clinical drug platform company developing therapies for neurodegenerative diseases including Alzheimer’s and Parkinson’s, reported significant third quarter 2025 progress, led by full activation of all 84 sites...